These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39293124)

  • 21. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis.
    Gordon-Lipkin E; Chodkowski B; Reich DS; Smith SA; Pulicken M; Balcer LJ; Frohman EM; Cutter G; Calabresi PA
    Neurology; 2007 Oct; 69(16):1603-9. PubMed ID: 17938370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.
    Novakova L; Axelsson M; Malmeström C; Imberg H; Elias O; Zetterberg H; Nerman O; Lycke J
    PLoS One; 2018; 13(4):e0194828. PubMed ID: 29614113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
    Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
    CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective study of disease modifying therapy and retinal atrophy in relapsing-remitting multiple sclerosis.
    Kabanovski A; Zaslavsky K; Rotstein D; Margolin E
    J Neurol Sci; 2023 Mar; 446():120552. PubMed ID: 36774748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
    J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis.
    Winges KM; Werner JS; Harvey DJ; Cello KE; Durbin MK; Balcer LJ; Calabresi PA; Keltner JL
    J Neuroophthalmol; 2013 Dec; 33(4):322-9. PubMed ID: 24051419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyper-reflective foci changes in RRMS under natalizumab therapy.
    Puthenparampil M; Basili E; Ponzano M; Mauceri VA; Miscioscia A; Pilotto E; Perini P; Rinaldi F; Bovis F; Gallo P
    Front Immunol; 2024; 15():1421755. PubMed ID: 39076978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis.
    Krämer J; Balloff C; Weise M; Koska V; Uthmeier Y; Esderts I; Nguyen-Minh M; Zimmerhof M; Hartmann A; Dietrich M; Ingwersen J; Lee JI; Havla J; Kümpfel T; Kerschensteiner M; Häußler V; Heesen C; Stellmann JP; Zimmermann HG; Oertel FC; Ringelstein M; Brandt AU; Paul F; Aktas O; Hartung HP; Wiendl H; Meuth SG; Albrecht P
    Nat Commun; 2024 Jun; 15(1):5243. PubMed ID: 38897994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of retinal vessel pathology and brain atrophy in relapsing-remitting multiple sclerosis.
    Romahn EF; Wiltgen T; Bussas M; Aly L; Wicklein R; Noll C; Berthele A; Dehmelt V; Mardin C; Zimmer C; Korn T; Hemmer B; Kirschke JS; Mühlau M; Knier B
    Front Immunol; 2023; 14():1284986. PubMed ID: 38090586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Bsteh G; Hegen H; Teuchner B; Amprosi M; Berek K; Ladstätter F; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2019 Feb; 25(2):196-203. PubMed ID: 29095097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis.
    Cellerino M; Priano L; Bruschi N; Boffa G; Petracca M; Novi G; Lapucci C; Sbragia E; Uccelli A; Inglese M
    J Neuroophthalmol; 2021 Sep; 41(3):329-334. PubMed ID: 33399416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trans-synaptic degeneration in the optic pathway: Exploring the role of lateral geniculate nucleus in early stages of relapsing-remitting multiple sclerosis.
    Miante S; Margoni M; Moretto M; Pengo M; Carmisciano L; Spolettini P; Silvestri E; Danieletto M; Franciotta S; Miscioscia A; Bertoldo A; Puthenparampil M; Gallo P
    Mult Scler Relat Disord; 2023 Sep; 77():104877. PubMed ID: 37454566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown RA; Nash RA; Griffith LM; Steinmiller KC; Devine SM; Hutton GJ; Popat U; Racke MK; Georges GE; Bowen JD; Arnold DL
    Mult Scler Relat Disord; 2021 Sep; 54():103149. PubMed ID: 34284316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Arroyo R; Bury DP; Guo JD; Margolin DH; Melanson M; Daizadeh N; Cella D
    Mult Scler; 2020 Jul; 26(8):955-963. PubMed ID: 31144568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axonal Degeneration Independent of Inflammatory Activity: Is It More Intense in the Early Stages of Relapsing-Remitting Multiple Sclerosis Disease?
    Cilingir V; Batur M
    Eur Neurol; 2020; 83(5):508-516. PubMed ID: 32957101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Racial differences in retinal neurodegeneration as a surrogate marker for cortical atrophy in multiple sclerosis.
    Lichtman-Mikol S; Razmjou S; Yarraguntla K; Bao F; Santiago-Martinez C; Seraji-Bozorgzad N; Bernitsas E
    Mult Scler Relat Disord; 2019 Jun; 31():141-147. PubMed ID: 30991300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal ganglion cell loss is associated with future disability worsening in early relapsing-remitting multiple sclerosis.
    Wauschkuhn J; Solorza Buenrostro G; Aly L; Asseyer S; Wicklein R; Hartberger JM; Ruprecht K; Mühlau M; Schmitz-Hübsch T; Chien C; Berthele A; Brandt AU; Korn T; Paul F; Hemmer B; Zimmermann HG; Knier B
    Eur J Neurol; 2023 Apr; 30(4):982-990. PubMed ID: 36635219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative T
    Harper JG; York EN; Meijboom R; Kampaite A; Thrippleton MJ; Kearns PKA; Valdés Hernández MDC; Chandran S; Waldman AD;
    Eur Radiol; 2024 Jun; 34(6):3826-3839. PubMed ID: 37943312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.